# Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval

- URL: https://talkfuse.com/story/eli-lillys-foundayo-obesity-pill-eases-sleep-apnea-in-late-stage-trial-paving-way-for-approval/
- Published: 2026-11-09T14:30:01+00:00
- Updated: 2026-11-09T21:50:17+00:00
- Original publisher: CNBC (publisher lean: Centre)
- Original article: https://www.cnbc.com/2026/11/09/eli-lilly-foundayo-sleep-apnea-trial.html
- Topics: Business

## Key points

- Foundayo reduced sleep apnoea events in two late-stage trials.
- Benefits were reported with and without PAP therapy.
- Some participants stopped treatment because of side effects.

## Summary

Eli Lilly says its obesity pill Foundayo reduced obstructive sleep apnoea symptoms in two late-stage trials, potentially supporting an application to approve it for the condition. The results suggest the pill could help people who do not use positive airway pressure therapy, as well as those who continue using it.

The studies included 363 people not using PAP therapy and 349 who were using it. After 52 weeks, average breathing interruptions fell by 21.1 per hour in the first group and 18.3 in the second, compared with reductions of 4.8 and 5.5 for placebo. Lilly reported weight loss of about 11% across groups; gastrointestinal side effects were common, and 12% of those not using PAP stopped the pill because of side effects.

---
Summarised by TalkFuse (https://talkfuse.com/). Quote the original publisher for the reporting and link this page for the summary and discussion.